|
[1]Giorgio B, Lucia M, Flora M, et al.Prevalence of and risk factorsfor nonalcoholic fatty liver disease:the dionysos nutrition and liverstudy[J].Hepatology, 2005, 42 (1) ∶44-52.
|
|
[2]Fan JG, Zhu J, Li XJ, et al.Prevalence of and risk factors for fattyliver in a general population of Shanghai, China[J].J Hepatol, 2005, 43 (3) ∶508-514.
|
|
[3]McCullough AJ.Pathophysiology of nonalcoholic steatohepatitis[J].JClin Gastroenterol, 2006, 40 (Suppl 1) ∶S17-S29.
|
|
[4]Chitturi S, Abeygunasekera S, Farrell GC, et al.NASHand insulinresistance:Insulin hypersecretion and specific association with theinsulin resistance syndrome[J].Hepatology, 2002, 35∶373-379.
|
|
[5]Franzise A, Vajro P, Argenziano A, et al.Liver in volvement inobese children:ultrasonography and liver enzymelevels at diagnosisand during follow-up in an Italian population[J].Dig Dis Sci, 1997, 42 (7) ∶1428-1432.
|
|
[6]Giulio M, Mara B, Antoniom L, et al.Association of nonalcoholicfatty liver disease with insulin resistance[J].Am J Med, 1999, 107 (5) ∶450-455.
|
|
[7]Silverman JF, O'brien KF, Long S, et al.Liver pathology in morbid-ly obese patients with and without diabetes[J].Am J Gastroenterol, 1990, 85 (10) ∶1349-1355.
|
|
[8]Singh H, Pollock R, Uhanova J, et al.Sympotoms of obstructivesleep apnea in patients with nonalcoholic fatty liver disease[J].DigDis Sci, 2005, 50 (12) ∶2338-2343.
|
|
[9]Hanley AJ, Williams K, Festa A, et al.Elevations in markers of liv-er injury and risk of type 2 diabetes:The Insulin Resistance Athero-sclerosis Study[J].Diabetes, 2004, 53 (10) ∶2623-2632.
|
|
[10]Cerda C, P啨rez-Ayuso RM, Riquelme A, et al.Nonalcoholic fattyliver disease in women with polycystic ovary syndrome[J].J Hepatol, 2007 May 24∶[Epub ahead of print].
|
|
[11]Day C P, James O F W.Steatohepatitis:a tale of two“hits”[J].Gastroenterology, 1998, 114 (4) ∶842-845.
|
|
[12]Hanley AJ, Williams K, Festa A, et al.Liver Markers and Devel-opment of the Metabolic Syndrome:The Insulin Resistance Athero-sclerosis Study[J].Diabetes, 2005, 54 (11) ∶3140-3147.
|
|
[13]Marchesini G, Bugianesi E, Forlani G, et al.Nonalcoholic fattyliver, steatohepatitis, and the metabolic syndrome[J].Hepatology, 2003, 38 (2) ∶53-56.
|
|
[14]Angulo P.Nonalcoholic fatty liver disease[J].N Engl J Med, 2002, 346 (16) ∶1221-1231.
|
|
[15]Chitturi S, Farrell GC.Etiopathogenesis of nonalcoholic steatohepa-titis[J].Semin Liver Dis, 2001, 21 (1) ∶27-41.
|
|
[16]Day CP.Pathogenesis of steatohepatitis[J].Best Pract Res ClinGastroenterol, 2002, 16 (5) ∶663-678.
|
|
[17]Yang H, Li YY, Nie YQ, et al.The relationship between insulinresistance and adiponectin gene expression in nonalcoholic fatty liverdisease[J].Chin J Hepatol, 2007, 15 (7) ∶525-528.
|
|
[18]Hotamisligil GS, Shargill NS, Spiegelman BM.Adipose expressionof tumor necrosis factor-alpha:direct role in obesity-linked insulinresistance[J].Science, 1993, 259 (5091) ∶87-91.
|
|
[19]Uysal KT, Wiesbrock SM, Marino MW, et al.Protection from obe-sity-induced insulin resistance in mice lacking TNF-alphafunction[J].Nature, 1997, 389 (6691) ∶610-614.
|
|
[20]Marchesini G, Brizi M, Bianchi G, et al.Nonalcoholic fatty liverdisease:a feature of the metabolic syndrome[J].Diabetes, 2001, 50 (8) ∶1844-1850.
|
|
[21]Marchesini G, Brizi M, Moreselli-Labate AM, et al.Associationof nonalcoholic fatty liver disease with insulin resistance[J].Am JMed, 1999, 107 (5) ∶450-455.
|
|
[22]Petersen KF, Dufour S, Befroy D, et al.Reversal of nonalcoholichepatic steatosis, hepatic insulin resistance and hyperglycemia bymoderate weight reduction in patients with type 2 diabetes[J].Diabe-tes, 2005, 54 (3) ∶603-608.
|
|
[23]Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, etal.Insulin sensitizers in treatment of nonalcoholic fatty liver disease:Systematic review[J].World J Gastroentero, 2006, 12 (48) ∶7826-7831.
|
|
[24]Bloomgarden ZT.Second World Congress on the Insulin ResistanceSyndrome:insulin resistance syndrome and nonalcoholic fatty liverdisease[J].Diabetes Care, 2005, 28 (3) ∶1518-1523.
|
|
[25]Schwimmer JB, Middleton MS, Deutsch R, et al.A phase 2 clini-cal trial of metformin as a treatment for non-diabetic paediatric non-alcoholic steatohepatitis[J].Aliment Pharmacol Ther, 2005, 21 (7) ∶871-879.
|
|
[26]Nair S, Diehl AM, Wiseman M, et al.Metformin in the treatmentof non-alcoholic steatohepatitis:a pilot open label trial[J].AlimentPharmacol Ther, 2004, 20 (1) ∶23-28.
|
|
[27]Kugelmas M, Hill DB, Vivian B, et al.Cytokines and NASH:a pi-lot study of the effects of lifestyle modification and vitamin E[J].Hepatology, 2003, 38 (2) ∶413-419.
|
|
[28]Manning PJ, Sutherland WH, Walker RJ, et al.Effect of high-dose vitamin E on insulin resistance and associated parameters in o-verweight subjects[J].Diabetes Care, 2004, 27 (9) ∶2166-2171.
|
|
[29]Ding X, Saxena NK, Lin S, et al.Exendin-4 a glucagon-likeprotein-1 (GLP-1) receptor agonist, reverses hepatic steatosis inob/ob mice[J].Hepatology, 2006, 43 (1) ∶173-181.
|
|
[30]Shimomura I, Hammer RE, Ikemoto S, et al.Leptin reverses insu-lin resistance and diabetes mellitus in mice with congenital lipodystro-phy[J].Nature, 1999, 401 (6748) ∶73-76.
|
|
[31]Yoon D, Lee SH, Park HS, et al.Hypoadiponectinemia and insu-lin resistance are associated with nonalcoholic fatty liver disease[J].Korean Med Sci, 2005, 20 (3) ∶421-426.
|
PDF下载 ( 176 KB)
本文二维码
下载:
